Ervogastat (PF-06865571): A Novel DGAT2 Inhibitor for Metabolic Dysfunction-Associated Steatohepatitis

1. Introduction to Ervogastat (PF-06865571)

Overview and Significance in NASH/MASH Treatment Landscape

Ervogastat, also known by its development code PF-06865571, is an investigational small molecule therapeutic agent currently under development by Pfizer Inc..[1] This compound has garnered attention as a potentially significant advancement in the challenging field of Metabolic Dysfunction-Associated Steatohepatitis (MASH), a condition previously referred to as Non-alcoholic Steatohepatitis (NASH). The focus of ervogastat's development is particularly on patients who present with liver fibrosis, a critical factor in disease progression.[2]

The landscape of MASH treatment is characterized by a profound unmet medical need. It is a progressive liver disease that, until very recently, had no therapies approved by major regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).[4] The potential consequences of untreated MASH are severe, including the development of cirrhosis, liver failure, and hepatocellular carcinoma, underscoring the urgency for effective pharmacological interventions.[4]